Pixium Vision is a bioelectronics technology company specialized in neuromodulation to restore a form of prosthetic vision to compensate for blindness. The organization uses implantable prostheses to compensate for vision loss and blindness from retinal degeneration, such as Dry Age-Related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP), enabling partial central visual perception. The solution involves micro-electronics, opto-electronics, neurobiology, and intelligent software algorithms.In January 2021, Pixium Vision and Second Sight Medical Products Inc, announced that they have entered into a definitive business combination agreement.In June 2023, Pixium Vision SA received a 1.8 million Research Tax Credit.In October 2022, Pixium Vision SA declared a cash position of €8.5 million.In January 2021, (i) Pixium Vision will contribute to Second Sight all of its assets and liabilities in relation to its neuromodulation technology used in the treatment of blindness in ex